CanSino Biologics Inc.
(康希諾生物股份公司)
(A joint stock company incorporated in the People’s Republic of China with limited liability)
(Stock code: 6185)

INSIDE INFORMATION

RECOMBINANT NOVEL CORONAVIRUS VACCINE
(ADENOVIRUS TYPE 5 VECTOR)
APPROVED FOR CLINICAL TRIAL

This announcement is made by CanSino Biologics Inc. (the “Company”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Recombinant Novel Coronavirus Disease Vaccine (Adenovirus Type 5 Vector) (the “Ad5-nCoV”), a vaccine jointly developed by the Company and the Institute of Biotechnology, Academy of Military Medical Sciences, was approved for clinical trial after registration documents review.

Ad5-nCoV is a genetic engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein, which intends to be used to prevent the disease caused by the novel coronavirus infection.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The safety and efficacy of Ad5-nCoV is subject to confirmation by clinical trials and we cannot guarantee that we will ultimately develop or market Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, March 18, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.